Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Impel Pharmaceuticals Inc (IMPL) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Impel Pharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1445499.
Total stock buying since 2021: $36,779,890.
Total stock sales since 2021: $74,130.
Total stock option exercises since 2021: $261,797.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 0 | $0 | 575,000 | $74,130 | 0 | $0 |
| 2022 | 0 | $0 | 0 | $0 | 56,319 | $48,473 |
| 2021 | 2,455,000 | $36,779,890 | 0 | $0 | 93,384 | $213,324 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-12 | 0 | $0 | 575,000 | $74,130 | 0 | $0 |
| 2022-12 | 0 | $0 | 0 | $0 | 31,713 | $0 |
| 2022-03 | 0 | $0 | 0 | $0 | 24,606 | $48,473 |
| 2021-12 | 0 | $0 | 0 | $0 | 20,000 | $32,800 |
| 2021-11 | 10,000 | $107,550 | 0 | $0 | 0 | $0 |
| 2021-09 | 0 | $0 | 0 | $0 | 73,384 | $180,524 |
| 2021-08 | 20,000 | $297,340 | 0 | $0 | 0 | $0 |
| 2021-04 | 2,425,000 | $36,375,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-12-19 | Vivo Capital Surplus Fund Viii, L.p. | Sale | 237,289 | .08 | 18,983 |
| 2023-12-18 | Vivo Capital Surplus Fund Viii, L.p. | Sale | 237,711 | .11 | 26,148 |
| 2023-12-15 | Vivo Capital Surplus Fund Viii, L.p. | Sale | 100,000 | .29 | 28,999 |
| 2022-12-31 | Leaman John Harold (Chief Fin. & Business Officer) | Option Ex | 21,142 | .00 | 0 |
| 2022-03-29 | Shrewsbury Stephen B (Chief Medical Officer) | Option Ex | 24,606 | 1.97 | 48,473 |
| 2021-12-22 | Hoekman John (Chief Scientific Officer) | Option Ex | 20,000 | 1.64 | 32,800 |
| 2021-11-19 | Nelson Timothy S (Director) | Buy | 10,000 | 10.76 | 107,550 |
| 2021-09-21 | Shrewsbury Stephen B (Chief Medical Officer) | Option Ex | 73,384 | 2.46 | 180,524 |
| 2021-08-18 | Adams Adrian (COB, CEO and President) | Buy | 20,000 | 14.87 | 297,340 |
| 2021-04-27 | 5am Opportunities I (gp), Llc (10% Owner) | Buy | 575,000 | 15.00 | 8,625,000 |
| 2021-04-27 | Kossow Jon Erik (10% Owner) | Buy | 825,000 | 15.00 | 12,375,000 |
| 2021-04-27 | Vivo Capital Surplus Fund Viii, L.p. | Buy | 575,000 | 15.00 | 8,625,000 |
| 2021-04-27 | Adelman Robert J | Buy | 450,000 | 15.00 | 6,750,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of IMPL listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Impel Pharmaceuticals Inc (symbol IMPL, CIK number 1445499) see the Securities and Exchange Commission (SEC) website.